BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND FANCF, FAF, 2188, ENSG00000183161, Q9NPI8, MGC126856 AND Treatment
13 results:

  • 1. Difference in SARS-CoV-2 Antibody Status Between Patients With cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
    Yazaki S; Yoshida T; Kojima Y; Yagishita S; Nakahama H; Okinaka K; Matsushita H; Shiotsuka M; Kobayashi O; Iwata S; Narita Y; Ohba A; Takahashi M; Iwasa S; Kobayashi K; Ohe Y; Yoshida T; Hamada A; Doi T; Yamamoto N
    JAMA Oncol; 2021 Aug; 7(8):1141-1148. PubMed ID: 34047762
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
    BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Berunda Polypeptides Carrying Rapalogues Inhibit Tumor mTORC1 Better than Oral Everolimus.
    Peddi S; MacKay JA
    Biomacromolecules; 2020 Aug; 21(8):3038-3046. PubMed ID: 32484665
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Insufficient lymph node assessment in gastric adenocarcinoma.
    Khanjani N; Mirzaei S; Nasrolahi H; Hamedi SH; Mosalaei A; Omidvari S; Ahmadloo N; Ansari M; Sobhani F; Mohammadianpanah M
    J Egypt Natl Canc Inst; 2019 Oct; 31(1):2. PubMed ID: 32372269
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/fancf/REV1-mediated DNA damage response.
    Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
    Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Zinc-modified Nanotransporter for Target Drug Therapy of breast cancer].
    Skaličková S; Gargulák M; Löffelmann M; Ruttkay-Nedecký B; Kepinská M; Parák T; Kizek R
    Klin Onkol; 2017; 30(Supplementum1):174-176. PubMed ID: 28471199
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
    Ring BZ; Hout DR; Morris SW; Lawrence K; Schweitzer BL; Bailey DB; Lehmann BD; Pietenpol JA; Seitz RS
    BMC Cancer; 2016 Feb; 16():143. PubMed ID: 26908167
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The Fanconi anemia pathway sensitizes to DNA alkylating agents by inducing JNK-p53-dependent mitochondrial apoptosis in breast cancer cells.
    Zhao L; Li Y; He M; Song Z; Lin S; Yu Z; Bai X; Wang E; Wei M
    Int J Oncol; 2014 Jul; 45(1):129-38. PubMed ID: 24789349
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. RNA interference-mediated fancf silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
    He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
    Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Gene silencing of fancf potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.
    Li Y; Zhao L; Sun H; Yu J; Li N; Liang J; Wang Y; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
    PLoS One; 2012; 7(8):e44254. PubMed ID: 22952942
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Assessing gynecologic and breast cancer survivors' sexual health care needs.
    Hill EK; Sandbo S; Abramsohn E; Makelarski J; Wroblewski K; Wenrich ER; McCoy S; Temkin SM; Yamada SD; Lindau ST
    Cancer; 2011 Jun; 117(12):2643-51. PubMed ID: 21656742
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Estrogen receptor alpha, BRCA1, and fancf promoter methylation occur in distinct subsets of sporadic breast cancers.
    Wei M; Xu J; Dignam J; Nanda R; Sveen L; Fackenthal J; Grushko TA; Olopade OI
    Breast Cancer Res Treat; 2008 Sep; 111(1):113-20. PubMed ID: 17932744
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Malignant phyllodes tumor with liposarcomatous differentiation. Description of a clinical case].
    Scala M; Mereu P; Comandini D; Nocentini L; Vecchio C
    Minerva Chir; 1999 May; 54(5):355-8. PubMed ID: 10443117
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.